Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

National Health And Medical Research Council Funding For UQ Brain Injury Research, Australia
University of Queensland researchers will use a $2.5 million grant to help people who have suffered an acquired brain injury communicate with the world.
new payday loan lenders
Chinese Government Reports Abortion Statistics
Chinese state media on Thursday reported that women in the country have about 13 million abortions annually, the AP/Houston Chronicle reports. According to the China Daily newspaper, the actual number likely is much higher because the 13 million includes abortions performed in hospitals but not unreported procedures performed in rural clinics. Most of the abortions were among single young women who experts say know little about contraception. The paper also said that about 10 million pills for medical abortion are sold annually in the country. China imposed strict population controls in the 1970s that prohibit most couples from having more than one child. For married women, sterilization and the use of intrauterine devices are widely promoted and subsidized. However, Chinese policies typically do not address the needs of unmarried women, even as national attitudes have become more accepting of sex outside of marriage, the AP/Chronicle reports. According to the newspaper, about 62% of the abortions were among unmarried women ages 20 to 29. The Chinese report called the number of abortions "an unfortunate situation" but did not indicate whether the procedures are increasing or decreasing from year to year. National Population and Family Planning Commission official Wu Shangchun is quoted in the report as saying that almost half of the women seeking abortion had used no form of contraception. Wu also said that reducing abortions is a national challenge that requires significant effort. Peking University professor Li Ying said that sex education in China must be improved at the university level and that Chinese parents must do more to teach children about sex (AP/Houston Chronicle, 7/30).
News of the day
Deep Vein Thrombosis: The Risk During A Flight Is Often Overestimated
The risk of developing deep vein thrombosis during a long flight is often overestimated. According to the German Institute for Quality and Efficiency in Health Care (IQWiG), this condition is very unlikely in healthy travellers. When people wear a cast or splint after a sports accident, on the other hand, many are not aware that they have an increased risk of deep vein thrombosis in their leg and pelvic area. This is emphasised in information published on IQWiG"s website Informed Health Online.
Endocrinology

Cepheid Receives FDA Clearance For First On-Demand Molecular Diagnostic Test For Clostridium Difficile Infection

Cepheid (Nasdaq: CPHD) announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) C. difficile test, an on-demand molecular diagnostic test designed for 45-minute detection of the bacterium that causes Clostridium difficile infection (CDI). The Xpert C. difficile test is the first test for CDI to deliver both rapid turnaround and a high degree of accuracy. "The previous lack of an accurate and rapid diagnostic test for CDI has greatly impeded our ability to halt the increasing rate of CDI, which has taken a severe turn in the past several years. Patients can have their first diarrhea symptoms on a Monday and be dead by Thursday," said Dale Gerding, MD, professor of medicine, division of infectious diseases, Loyola University Chicago Stritch School of Medicine. "Toxigenic culture offers high sensitivity, but laboratories find it burdensome and far too slow for practical diagnostic use. Instead, many use less labor-intensive toxin EIA (enzyme immunoassay) and GDH (glutamate dehydrogenase) tests, which fail to detect 20-50% of cases. From a practical standpoint, this means many patients are not subjected to proper isolation procedures that can curtail transmission of C. difficile. A rapid, accurate CDI test will eliminate needless repetitive testing and enable us to implement appropriate treatment and infection control measures faster in our battle against this devastating Healthcare Associated Infection." C. difficile, a spore-forming bacterium, is now challenging Methicillin-resistant Staphylococcus aureus (MRSA) as the most prevalent Healthcare Associated Infection (HAI) in the United States. A recent study published by the Association for Professionals in Infection Control and Epidemiology (APIC) found that on any given day there are more than 7,000 patients in the United States suffering from CDI, causing the deaths of approximately 300 patients per day. The disease, which can range in severity from mild to severe diarrhea, pseudomembranous colitis, toxic megacolon, sepsis, and death, is costing American healthcare institutions up to $51.5 million per day. "As the leader in molecular HAI testing, it is incumbent for Cepheid to provide healthcare institutions access to the most comprehensive suite of rapid and accurate HAI tests on the market. The Xpert C. difficile test establishes new levels of speed, accuracy, and ease-of-use for CDI testing," said John Bishop, Cepheid"s Chief Executive Officer. "As Cepheid continues the development of innovative new diagnostic solutions, we will strive to measure our product design against a solid understanding of healthcare"s current, and future, needs for rapid and accurate diagnostic tests. Our novel approach for the Xpert C. difficile test, as measured against the true gold standard of toxigenic culture, delivered on that vision." As CDI rates continue to rise throughout the world, a more virulent epidemic strain, known as 027/NAP1/BI, has now been detected in at least 48 states, Canada, and throughout Europe. The Xpert C. difficile test has been cleared for the direct detection of toxigenic Clostridium difficile from stool specimens. The test targets the Toxin B gene, discovered in 1978 to be the cause of antibiotic-associated diarrhea and colitis. The Toxin B (tcdB) gene is the critical component of all toxigenic Clostridium difficile strains -- including the epidemic 027/NAP1/BI strain. Cepheid will also continue to work closely with the FDA to deliver an additional product featuring simultaneous differentiation of the 027/NAP1/BI epidemic strain. The Xpert C. difficile test is Cepheid"s seventh test to receive FDA clearance, and fourth in its expanding menu of on-demand HAI products. The test, which runs on Cepheid"s GeneXpert(R) System, will be available for shipment the week of July 20th. About the GeneXpert System The GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment. About Cepheid Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company"s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company"s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009